Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

SAN ANTONIO — Promising data don’t always equal a stock pop. Viking Therapeutics presented what analysts thought were compelling data on an oral GLP-1/GIP dual agonist on Sunday evening, but the market reacted ...